Sergio Moral

Dr. Sergio Moral

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
SMSergio Moral
Sergio Moral
EBEsther Ballesteros
Esther Ballesteros
MHMarina Huguet
Marina Huguet
APAlejandro Panaro
Alejandro Panaro
JPJordi Palet
Jordi Palet
AEArturo Evangelista
Arturo Evangelista

1 November 2012 in International Journal of Cardiology
Verified
Journal Article
Closed access
SMSergio Moral
Sergio Moral
LFLeticia Fernández-Friera
Leticia Fernández-Friera
GSGerin Stevens
Gerin Stevens
GGGabriela Guzman
Gabriela Guzman
AGAna García-Alvarez
Ana García-Alvarez
JSJavier Sanz
Javier Sanz

1 November 2012 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
SMSergio Moral
Sergio Moral
JRJose Rodríguez-Palomares
Jose Rodríguez-Palomares
MDMartín Descalzo
Martín Descalzo
GMGerard Martí
Gerard Martí
VPVíctor Pineda
Víctor Pineda
DGDavid García-Dorado
David García-Dorado

25 July 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
SMSergio Moral
Sergio Moral
EBEsther Ballesteros
Esther Ballesteros
MRMarta Roque
Marta Roque
CCCristina Carrato
Cristina Carrato
PVPau Vilardell
Pau Vilardell
AEArturo Evangelista
Arturo Evangelista

6 June 2023 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
NCNúria Coma
Núria Coma
SMSergio Moral
Sergio Moral
EBEsther Ballesteros
Esther Ballesteros
AEArantxa Eraso
Arantxa Eraso
MVMontse Ventura
Montse Ventura
RBRamon Brugada
Ramon Brugada
Cancer and its treatments affect cardiovascular (CV) health, including an increased risk of CV death, decreased cardiorespiratory fitness (CRF), and cardiac dysfunction. Moreover, cancer-related fatigue and worse quality of life (QoL) are highly prevalent adverse effects experienced by patients during treatment and can persist years after therapy ends. Physical exercise has been proposed as a strategy to improve different aspects of life of cancer patients, and is recommended as a therapy in cardio-oncology guidelines. Exercise interventions reduce fatigue and improve QoL in patients with both solid tumors and hematological malignancies, although there is a lack of awareness of exercise recommendations, timing, and referral to such programs. New evidence indicates that physical activities improve CRF, which can lead to a reduction in CV mortality. Furthermore, cardiac dysfunction is a side effect of many oncological treatments, which may be mitigated by exercise interventions according to preclinical studies and recent publications. Nevertheless, specific physical exercise programs are not widely used in cancer patients. Thus, the goal of this review was to describe the current evidence on the benefits of exercise in cancer patients, the gaps that remain, and an approach to exercise prescription.

28 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PVPau Vilardell
Pau Vilardell
SMSergio Moral
Sergio Moral
DBDaniel Bosch
Daniel Bosch
MMManel Morales
Manel Morales
JFJosep Maria Frigola
Josep Maria Frigola
RBRamon Brugada
Ramon Brugada
Right-sided infective endocarditis (RSIE), classically associated with intravenous drug use or intracardiac devices, is considered a good-prognosis infective endocarditis (IE) form. However, predisposing factors and prognosis for “NODID” RSIE (NOt associated with cardiac Devices or Intravenous Drug use) remain unclear. The aim of this study was to evaluate predisposing factors and prognosis of NODID RSIE compared to other RSIE forms. A retrospective cohort study (January 2008–January 2019) was conducted in a reference center on 300 patients diagnosed with IE. Endocarditis-related events were defined as related to IE in mortality or open-heart surgery during follow-up. A review and meta-analysis of associated literature (January 2008-January 2019) were also performed. Fifty-seven patients presented RSIE (19%), 22 of which were NODID RSIE (39%). Use of intravascular catheters (23% vs 3%; p = 0.027) and congenital heart diseases (18% vs 0%; p = 0.019) were associated with NODID RSIE. This group had a higher in-hospital mortality (23% vs 3%; p = 0.027) and endocarditis-related event rates (41% vs 6%; p = 0.001) than non-NODID RSIE. Furthermore, NODID RSIE was independently associated with in-hospital endocarditis-related events (OR = 19.29; 95%CI:2.23–167.16; p = 0.007). Our meta-analysis evaluated four studies and identified 96 cases (30%) of NODID RSIE from 320 total RSIE cases. NODID RSIE patients demonstrated higher in-hospital mortality (RR = 2.81; 95%CI:1.61–4.90; p < 0.001; I2 = 0.0%) and necessity of open-heart surgery (RR = 13.89; 95%CI:4.14–46.60; p < 0.001; I2 = 0.0%) than non-NODID RSIE cases. Our study suggests that NODID RSIE has the highest endocarditis-related event rate and in-hospital mortality among RSIE cases and therefore should not be considered a good-prognosis IE.